Vamecq J, Lambert D, Poupaert J H, Masereel B, Stables J P
INSERM/CHRU Lille, Domaine du Certia, 369 rue Jules Guesde, BP 39, 59651 Villeneuve d'Ascq Cedex, France.
J Med Chem. 1998 Aug 27;41(18):3307-13. doi: 10.1021/jm9608772.
Fifteen compounds related to ameltolide (LY 201116) were studied for (i) anticonvulsant potential in the maximal electroshock-induced seizures (MES) and the subcutaneous pentylenetetrazol (sc Ptz) tests in mice and rats and (ii) interactions with neuronal voltage-dependent sodium channels. Compounds were chosen ranging in anticonvulsant activity in mice from very active to inactive. The active compounds were defined as those protecting 50% of the animals at doses between 10 and 50 micromol/kg and inactive compounds as those protecting 50% of the animals at doses greater than 1 mmol/kg. The series studied included three N-(2,6-dimethylphenyl)benzamides (compounds 1, 2 (ameltolide), and 3), three N-(2,2,6, 6-tetramethyl)piperidinyl-4-benzamides (compounds 4, 5, 6), one phenylthiourea (compound 7), five N-(2,6-dimethylphenyl)phthalimides (compounds 8, 9, 10, 13, and 14), two N-phenylphthalimide derivatives (compounds 11 and 12), and one N-(2,2,6, 6-tetramethyl)piperidinyl-4-phthalimide (compound 15). Phenytoin (PHT) was employed as the reference prototype antiepileptic drug. After inital screening in mice, compounds 1, 2, 3, 5, 8, 9, 10, 13, and 14 were selected for further testing in rats. Anticonvulsant ED50s (effective doses in at least 50% of animals tested) of compounds in the MES test were determined in rats dosed orally and amounted to 52 (1), 135 (2), 284 (3), 231 (8), 131 (9), 25 (10), 369 (13), 354 (14), and 121 (PHT) micromol/kg, compound 5 presenting with an ED50 value higher than 650 micromol/kg. In our hands, the apparent IC50s (inhibitory concentrations 50) of compounds toward binding to rat brain synaptosomes of [3H]batrachotoxinin-A-20alpha-benzoate were 0.25 (1), 0.97 (2), 0.35 (3), 25.8 (5), 161.3 (8), 183.5 (9), 0.11 (10), 1.86 (13), 47.8 (14), and 0.86 (PHT) microM. The relationship between the activity in the MES test and the capacity to interact in vitro with neuronal voltage-dependent sodium channels and the fact that the IC50 values obtained in the in vitro test are close to the brain concentrations at which anticonvulsant activities are reported to occur for ameltolide strongly suggest that the anticonvulsant properties of most compounds tested could be a direct result of their interaction with the neuronal voltage-dependent sodium channel.
对15种与阿美托利德(LY 201116)相关的化合物进行了研究,以考察其:(i)在小鼠和大鼠的最大电休克诱导惊厥(MES)及皮下注射戊四氮(sc Ptz)试验中的抗惊厥潜力;(ii)与神经元电压依赖性钠通道的相互作用。所选择的化合物在小鼠中的抗惊厥活性范围从非常活跃到无活性。活性化合物定义为在10至50微摩尔/千克剂量下能保护50%动物的化合物,无活性化合物定义为在剂量大于1毫摩尔/千克时能保护50%动物的化合物。所研究的系列包括三种N -(2,6 - 二甲基苯基)苯甲酰胺(化合物1、2(阿美托利德)和3)、三种N -(2,2,6,6 - 四甲基)哌啶基 - 4 - 苯甲酰胺(化合物4、5、6)、一种苯硫脲(化合物7)、五种N -(2,6 - 二甲基苯基)邻苯二甲酰亚胺(化合物8、9、10、13和14)、两种N - 苯基邻苯二甲酰亚胺衍生物(化合物11和12)以及一种N -(2,2,6,6 - 四甲基)哌啶基 - 4 - 邻苯二甲酰亚胺(化合物15)。苯妥英(PHT)用作参考原型抗癫痫药物。在小鼠中进行初步筛选后,选择化合物1、2、3、5、8、9、10、13和14在大鼠中进行进一步测试。在大鼠口服给药后,测定了这些化合物在MES试验中的抗惊厥ED50(至少在50%受试动物中有效的剂量),分别为52(1)、135(2)、284(3)、231(8)、131(9)、25(10)、369(13)、354(14)和121(PHT)微摩尔/千克,化合物5的ED50值高于650微摩尔/千克。在我们的实验中,化合物与[3H]蟾毒素-A - 20α - 苯甲酸酯结合至大鼠脑突触体的表观IC50(半数抑制浓度)分别为0.25(1)、0.97(2)、0.35(3)、25.8(5)、161.3(8)、183.5(9)、0.11(10)、1.86(13)、47.8(14)和0.86(PHT)微摩尔。MES试验中的活性与体外与神经元电压依赖性钠通道相互作用的能力之间的关系,以及体外试验中获得的IC50值接近据报道阿美托利德产生抗惊厥活性的脑内浓度这一事实,强烈表明大多数受试化合物的抗惊厥特性可能是它们与神经元电压依赖性钠通道相互作用的直接结果。